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Abstract 
Rat pancreatic islets exposed to interleukin-l/l (IL-l/-7) in the presence of succmic acid monomethyl ester (SAM) have a higher insulin release in 
response to glucose and higher glucose oxidation rates, as compared to islets exposed to IL-l/l alone. These beneficial effects of SAM were not 
accompanied by any decrease in IL-l/3-induced nitric oxide (NO) production nor inhibition of aconitase activity. Moreover, SAM did not increase 
biosynthesis of glutamate decarboxylase. SAM apparently improves B-cell function mostly by increasing the capacity of these cells to endure NO 
exposure and partial blockage of the Krebs cycle. 
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1. Introduction 
The autoimmune process leading to insulin-dependent 
diabetes mellitus may evolve for several years before the 
clinical onset of the disease [l]. During this period, a 
negative balance between /?-cell damage and repair pro- 
gressively decreases /?-cell mass (reviewed in [ 1,2]). Up to 
now, most clinical and experimental trials to prevent the 
outbreak of IDDM involved attempts to arrest the au- 
toimmune assault against the /?-cells [3]. It would also be 
of interest to increase the /?-cell capacity to repair itself. 
Indeed, nutrients such as glucose and amino acids, and 
the vitamin B,-derived compound nicotinamide, im- 
prove /?-cell function and survival following cytotoxic 
damage [2]. However, glucose and a-ketoisocaproic acid 
also increases the expression of glutamate decarboxylase 
(GAD) [46], a major islet cell autoantigen in IDDM [7]. 
This could potentially exacerbate the autoimmune as- 
sault against the p-cells. Moreover, prolonged exposure 
of these cells to hyperglycemia may be deleterious to 
B-cell function [S]. 
It has previously shown that methyl esters of succinic 
acid can be taken up and metabolized at the Krebs cycle 
level by pancreatic /?-cells, leading to increased insulin 
*Corresponding author. Fax: (46) (18) 556 401. 
biosynthesis and release [9-121. Interestingly, these esters 
also protect pancreatic islets in vivo against the diabeto- 
genie agent streptozotocin [13]. The ability of succinic 
acid esters to gain direct access to the Krebs cycle, by 
increasing the influx of both succinate and acetyl resi- 
dues [12], suggested that these esters may be useful in the 
treatment of non-insulin dependent diabetes mellitus 
(NIDDM). Indeed, the alteration of /?-cell secretory re- 
sponse to glucose in NIDDM may be due to a site- 
specific defect in the early steps of glucose metabolism, 
and these defects could be bypassed by succinate esters 
[ 141. In some experimental models of p-cell damage and 
dysfunction in IDDM there is also a site-specific impair- 
ment in glucose metabolism. Thus, when pancreatic islets 
are exposed to IL-l/I, a cytokine with potential role for 
/?-cell destruction in early IDDM [ 151, there is generation 
of nitric oxide (NO) [16-l 81. This radical leads to de- 
creased activity of the Krebs cycle enzyme aconitase [ 171, 
with consequent decrease in oxidative phosphorylation 
and /?-cell ATP production, impairment in insulin bio- 
synthesis and release, and eventually cell death [ 191. Con- 
sidering that succinate esters enter the Krebs cycle at 
steps distal to isocitric acid, the final product of aconitase 
activity, it would be of interest to evaluate if these esters 
can improve the function of pancreatic islets exposed to 
IL-B. In the present study we investigated the effects of 
succinic acid monomethyl ester (SAM) on the IL-l/3 ac- 
tions on rat pancreatic islets. Moreover, we also tested 
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if SAM leads or not to an increased biosynthesis of the 
/?-cell autoantigen GAD. 
2. Material and methods 
Pancreatic islets were isolated by collagenase digestion from adult 
male Sprague-Dawley rats bred in a local colony (Biomedical Centre, 
Uppsala, Sweden). After isolation the islets were cultured free-floating 
m medium RPM1 1640 containing 11.1 mM glucose and supplemented 
with 10% (volume/volume) fetal bovine serum [20]. The islets were 
precultured for 46 days under the conditions described above (medium 
was changed every two days) before exposure to 25 U/ml II-l/I with or 
without the addition of 10 mM SAM. Human recombinant IL-IS was 
kindly provided by K. Bendtzen, Laboratory of Medical Immunology, 
Rigshospitalet, Copenhagen, Denmark. The biological activity of IL-IS 
was 50 U/ng, as compared with an interim international preparation 
(NIBSC, London, UK). It has been previously shown in dose-response 
studies that 10 mM SAM induces a clear stimulation in islet insulin 
biosynthesis and release [l 11. After 24 h exposure to the different agents, 
the islets were harvested and used for the different experimental proce- 
dures. 
Insulin release, insulin and nitrite accumulation in the medium, islet 
DNA and insulin contents were determined as previously described 
[8,17]. Briefly, insulin release was studied in triplicate groups of 10 islets 
by a first hour incubation with 1.7 or 2.8 mM glucose. The incubation 
medium, Krebs-Ringer bicarbonate buffer (KRBH), was then gently 
removed and replaced by medium containing either 16.7 mM glucose 
or 2.8 mM glucose + 10 mM SAM and the incubation continued for 
a second 60-min period. For the determination of [U-r4C]glucose (293 
mCi/mM; Amersham International, UK) oxidation, triplicate groups 
of 10 islets were transferred to glass vials containing 100~1 KRBH and 
nonradioactive glucose to a final concentration of 16.7 mM glucose. 
Islet glucose oxidation was subsequently measured as described in de- 
tail elsewhere [8,17]. In these and the above described experiments, the 
mean of the triplicate observations was considered as one observation. 
Islet aconitase activity was determined in groups of 150 islets. as previ- 
ously described [171. 
For determination of GAD biosynthesis, groups of 200 islets were 
cultured for 24 h in the presence of IL-l/I and/or SAM, as described 
above. After this period the islets were washed twice with methionine- 
free RPM1 1640, and then incubated for 6 h in methionine-free RPM1 
1640 containing 10% dialyzed calf serum and [35S]methionine (>1100 
Ci/mmol; Amersham International). SAM and/or IL-l/I were present 
during the labelling period at the same concentration as in the previous 
24-h culture. After this, the islets were lysed and prepared for im- 
munoprecipitations as described elsewhere [4,6]. Lysates from islets 
cultured in each of the different experimental conditions were precipi- 
tated using two different sera, a rabbit anti-rat MHC class I antiserum 
(K271). and a sheep anti-rat GAD antiserum (NIMH-1440) reacting 
against both isoforms of GAD [21]. Immunocomplexes were collected 
and analysed by fluorography of sodium dodecylsulphate-poly- 
acrvlamide gel electrouhoresis (SDS-PAGE) 14.61. or scanned in a uhos- 
phor image;(Molecuiar Dynamics, Sunnyvale; CA) and analysed using 
the ImageQuant software program (Molecular Dynamics). The results 
are presented as the ratios between values for GAD and MHC class I. 
Data were computed as the mean + S.E.M. and compared using 
Student’s t-test for paired or unpaired samples, as appropriate. When 
multiple comparisons were performed, the data were analysed by anal- 
ysis of variance (ANOVA), followed by group comparisons using the 
Student’s r-test. The P values were corrected for multiple comparisons 
using the Bonferroni method [22]. 
3. Results 
Exposure of rat pancreatic islets to IL-l/? induced a 
50-70% decrease in both basal (1.7 mM) and glucose 
(16.7 mM)-stimulated insulin release (Table 1). Islets 
treated with IL-l/? + SAM have significantly higher in- 
sulin release in response to glucose than islets treated 
with IL-l/? alone. In line with these observations, islets 
exposed to IL-lb released less insulin into the culture 
medium (41% of the values observed in control islets; 
P < O.Ol), while islets exposed to IL-l/? in the presence 
of SAM have medium insulin values which were not 
significantly different from that observed in control 
(RPMI) or SAM (RPM1 + SAM) islets (data not 
shown). All experimental groups have similar islet insu- 
lin and DNA contents (data not shown). 
It has been previously suggested that the suppressive 
effects of IL-l/? on rat pancreatic islets are mediated by 
NO production and subsequent inhibition of the Krebs 
cycle enzyme aconitase [16-181. In order to investigate if
the protective effects of SAM were related to preventing 
IL-l/?-induced NO production and aconitase inhibition, 
we measured medium nitrite accumulation and islet aco- 
nitase activity (Table 1). As expected, IL-lp induced an 
increase in medium nitrite accumulation (see below) and 
a decrease in aconitase activity (Table 1). Control islets 
(RPMI) and islets exposed to SAM (RPM1 + SAM) 
have undetectable amounts of nitrite in the medium, 
Table 1 
Insulin release, glucose oxidation and aconitase activity of rat pancreatic islets cultured for 24 h in the presence of IL-l/I (25 U/ml) and/or succinic 
acid monomethyl ester (SAM; 10 mM) 
Culture condition Insulin release (ng insulin/10 islets.1 h) Glucose oxidation Aconitase activity 
(pmol/lO islets.15 h) (pmoYislet.min) 
1.7 mM glut 16.7 mM glut 
RPM1 10 + 2 99 f 6 513 f 62 27 f 3 
RPM1 + SAM 11 f2 129 f 10 471 + 48 31 f4 
RPM1 + IL-l/I 5f 1* 27 f 4**” 103 f 9*** 3f 1** 
RPM1 + IL-lb + SAM 7f2 76 f 10” 247 f lO*§ 4 f 1**5 
Insulin release was measured by incubating the islets in triplicate groups of 10 in KRBH buffer containing 1.7 mM glucose. After 1 h, the medium 
was exchanged for KRBH supplemented with 16.7 mM glucose. Glucose oxidation rate was measured in triplicate groups of 10 islets at 16.7 mM 
glucose, and aconitase activity was measured (after sonication) in groups of 150 islets, as described in section 2. Values are means + S.E.M. of 8-10 
separate experiments (insulin release), 6 experiments (glucose oxidation) or 4 experiments (aconitase activity). *P < 0.05 and **P < 0.001 when 
compared to RPM1 islets, ‘P < 0.01 when compared to RPM1 + IL-1B + SAM islets and §P < 0.01 when compared to RPM1 + SAM. 
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Fig. 1. Fluorography of an SDS-PAGE of immunoprecipitates from rat islets lysates labelled with [3ZS]methionine. In the upper margin, the lanes 
labelled a represent lysates of islets cultured in the presence of RPM1 only, the lanes labelled b islets cultured with RPM1 + 10 mM SAM, the lanes 
labelled c islets cultured with RPM1 + 25 U/ml IL-l/? and the lanes labelled d islets cultured with RPM1 + 25 U/ml IL-l/3 + 10 mM SAM. In the 
lower margin it is indicated the antiserum used in the immunoprecipitation: K271, a rabbit antiserum against the MHC class I, and NIMH-1440, 
a sheep antiserum against GAD. In the lateral margins the arrows indicate the approximate positions of GAD, the MHC class I heavy chain and 
/I2 microglobul~n, which is coprecipitated with the MHC class I by the K271 antiserum. In the ~ght-hand margin the position of molecular weight 
markers are depicted. 
while islets exposed to IL-l/3 (RPM1 + IL-l/I) presented 
high nitrite values (18.1 + 2.7 pmoVislet.24 h; 
mean + S.E.M.; n = 8), similar to the values observed in 
islets exposed to IL-l/3 + SAM (RPM1 + IL-lb + SAM; 
20.0 + 3.5 pmo~islet.24 h; n = 8). Thus, the effects of the 
cytokine on NO production and aconitase activity were 
not prevented by SAM. However, SAM partially pre- 
vented IL-lp-induced decrease in islet glucose oxidation 
(Table 1). Glucose metabolism of IL-la -t- SAM-treated 
islets was around 55% of the values observed in islets 
cultured in the presence of SAM alone, similar to the 
insulin release data, where values for the IL-l@ + SAM 
group were around 60% of the values observed in SAM 
islets (Table 1). On the other hand, islets exposed to 
IL-Ip alone have glucose oxidation and insulin release 
values which were only 20-30% of the values observed 
in the respective control islets (Table 1). 
When considering agents potentially able to improve 
p-cell function in early IDDM it is important to assess 
if these agents induce an increased biosynthesis and ex- 
pression of islet autoantigens. To test if these was the 
case for SAM, we determined the biosynthesis of GAD, 
an autoantigen in IDDM, in islets exposed to SAM and/ 
or IL-l/?. In four experiments, the immunoprecipitates 
separated by SDS-PAGE were analysed by fluorography 
(Fig. 1). By visual inspection, SAM or SAM + IL-l/I 
exposure did not increase GAD biosynthesis, as com- 
pared respectively to control islets or islets exposed to 
11-l. IL-lb decreased GAD expression, without affecting 
HLA class I expression. Quantitative analysis of im- 
munoprecipitable GAD by the phosphor imager (ex- 
pressed as the ratios between values corresponding to 
GAD and MHC class I) showed arbitrary values of 
0.57 f 0.10 (n = 4) in control islets, and 0.49 It 0.07 
(n = 4) in islets cultured in the presence of SAM. IL-l/3 
induced a marked decrease in GAD biosynthesis (IL-la, 
Table 2 
Insuhn release of rat pancreatic islets cultured for 24 h in the presence 
of IL-l@ (25 U/ml) and then exposed for 1 h to 16.7 mM glucose or 10 
mM SAM + 2.8 mM glucose 
Culture condition Insulin release (ng insulin/l0 islets. 1 h) 
2.8 mM glut 16.7 mM glut 10 mM SAM _._~ 
RPM1 13 * 3 87 + 9 
RPM1 + IL-I/I 7+ 1* 24 * 2** _ 
RPM1 15 + 3 _ 73 & 8 
RPM1 + IL-l/3 8f2 21 t 3** 
Insulin release was measured by incubating the islets m groups of 10 
in KRBH buffer containing 2.8 mM glucose. After 1 h, the medium was 
exchanged for KRBH supplemented with either 16.7 mM glucose or 10 
mM SAM + 2.8 mM glucose. Values are means + S.E.M. of 6 separate 
experiments, each performed in triplicate. ‘P < 0.05 and **p < 0.001 
when compared to respective control islets. 
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0.22 f 0.06, n = 4; P < 0.01 vs. control islets), and this 
decrease was not counteracted by SAM (IL-l/I + SAM, 
0.19 + 0.05; n = 4; P c 0.01 vs. control or SAM-treated 
islets). 
In a final series of experiments, the effects of a short- 
term (1 h) incubation in the presence of SAM on insulin 
release by islets exposed for 24 h to IL- l/I were evaluated 
(Table 2).As described in Table 1, 24h treatment with 
IL-l/I again induced a clear decrease in insulin release 
both at low and high glucose concentrations (Table 2). 
A similar defective insulin release was observed when 
islets were stimulated with 10 mM SAM instead of 16.7 
mM glucose. Indeed, in both cases insulin release was 
30% of that observed in control islets. 
4. Discussion 
The present data show that SAM partially protects rat 
pancreatic islets against the suppressive ffects of IL-1B. 
This conclusion is based on the observations that islets 
exposed to IL-l/3 in the presence of SAM have higher 
insulin release in response to glucose, preserved insulin 
accumulation into the culture medium and higher glu- 
cose oxidation rates than islets exposed to IL-1B alone. 
These beneficial effects of SAM were not accompanied 
by any stimulation of the biosynthesis of GAD, a major 
autoantigen in early IDDM [7]. This is specially relevant 
if one considers the potential use of SAM as an adjuvant 
therapy of early IDDM, aiming at improving p-cell sur- 
vival and function in the context of an ongoing autoim- 
mune assault. Indeed, other agents that may stimulate 
B-cell function, like glucose, a-ketoisocaproic acid and 
sulfonylureas, have previously been shown to also in- 
crease GAD biosynthesis, both in rodent [4,5] and 
human pancreatic islets [6]. To our knowledge, SAM is 
the first described agent which improves b-cell function 
without increasing GAD expression. 
The regulation of GAD expression in B-cells still re- 
mains to be clarified. Available data suggest hat GAD 
activity and expression usually parallels insulin biosyn- 
thesis and release [4-61. In agreement with this, SAM did 
not increase GAD biosynthesis, insulin release, insulin 
accumulation into the medium or islet insulin content in 
the control islets (not exposed to IL-l/3). Moreover, IL- 
l/I inhibited in parallel all these parameters. Interest- 
ingly, when islets were exposed to both IL-1B and SAM 
there was a clear inhibition of GAD biosynthesis without 
a similar impairment in insulin release. This suggest hat 
under specific conditions GAD synthesis may be dissoci- 
ated from insulin synthesis and release. Further charac- 
terization of this condition may help to clarify the con- 
trol of GAD expression in /?-cells. 
It has been previously proposed that the cytokine IL- 
l/I may be an important mediator of p-cell damage in 
early IDDM [15], probably by inducing generation of 
NO [l&l 81. Indeed, rodent insulin producing cells ex- 
posed to IL-1B express mRNA for the inducible form of 
nitric oxide synthase [23,24] and produce large amounts 
of NO [16-l 8,23,24]. This radical leads to impairment in 
mitochondrial function, at least in part by blocking the 
activity of aconitase [ 171. IL-lp alone does not induce 
NO production nor inhibits function of human pancre- 
atic islets [25], but when these islets are exposed to com- 
binations of cytokines, namely IL-l/? + tumor necrosis 
factor-a + interferon-y, there is both induction of NO 
and impairment in islet function [26,27]. Based on these 
observations it has been suggested that NO, produced 
either by invading macrophages or by the p-cells them- 
selves, may be a final common pathway for B-cell dam- 
age in early IDDM [28,29]. In the present series of exper- 
iments, SAM protected the /?-cells without preventing 
IL- l/I-induced NO production or inhibition of aconitase 
activity. Thus, the beneficial actions of succinate are 
probably not related to interference with the initial steps 
of IL-l/? effects, such as binding to surface receptors, 
induction of iNOS mRNA transcription and NO pro- 
duction and blockage of aconitase activity. Indeed, SAM 
seems to improve /?-cell function mostly by increasing the 
ability of these cells to endure free radical exposure and 
impairment in substrate metabolism. It is noteworthy 
that when mouse pancreatic islets are exposed to IL-l/? 
there are similar NO generation as observed in rat pan- 
creatic islets [30]. Moreover, aconitase activity is also 
inhibited by IL-l/3 in mouse islets, but there is no signif- 
icant impairment in glucose metabolism or ATP genera- 
tion [31,32]. These observations suggest that mouse 
pancreatic islets are able to better endure a partial im- 
pediment of the Krebs cycle than rat islets. Apparently 
SAM improves this particular susceptibility of rat /?-cells 
to inhibition of the Krebs cycle. 
As mentioned above, prolonged islet exposure to IL- 
1B and NO affects ATP generation by blocking aconitase 
[17]. It is conceivable that NO also induces other delete- 
rious effects on /I-cells, like impairment in the mitochon- 
drial electron chain transport, inhibition of DNA synthe- 
sis and ADP-ribosylation of enzymes of the glycolytic 
pathway [33]. However, observations that the cytokine 
does not impair the glycolytic pathway [34] nor the con- 
version of pyruvate into the acetyl-coenzyme-A residues 
[35] emphasizes the importance of the inhibition at the 
Krebs cycle level. Interestingly, not all steps of the cycle 
are inhibited to the same extent by IL-l. Thus, while the 
cytokine impairs both glucose and leucine metabolism, 
it does not decrease the oxidation of glutamine [35]. Glu- 
tamine enters the Krebs cycle as ketoglutarate, in a step 
distal to the enzyme aconitase. If one considers that 
SAM gains access to the Krebs cycle mostly as succinate 
[12], also distal to aconitase, it is conceivable that the 
ester may increase FADH, and NADH generation and 
consequent ATP production by by-passing the decreased 
aconitase activity. Moreover, not all electrons from oxi- 
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dized substrates enter the electron chain transport at the 
NAD’ level, and electrons from succinate may pass from 
FAD directly to ubiquinone [36]. This can also contrib- 
ute to an improvement in cell function in the context of 
IL-l/&induced decreased NADH production. It must be 
emphasized that the protection afforded by SAM is par- 
tial, and that the ester does not improve islet function 
when added for a short period (1 h) following 24 h expo- 
sure to IL-&S. This suggests that there are some deleteri- 
ous effects induced by NO that can not be prevented by 
SAM and/or that the ester can not revert a situation 
characterized by severe cell damage, as observed follow- 
ing 24 h exposure to IL-l/?. 
Up to now most attempts to prevent the outbreak of 
IDDM have been directed towards suppression of the 
autoimmune assault [3]. Recent data suggest hat in this 
context attention must also be paid to repair mechanisms 
triggered by the /?-cells (reviewed in [2]). It may well be 
that SAM, by providing a substrate that can be effec- 
tively oxidized by damaged /3-cells, is providing the en- 
ergy that will allow a more efficient activation of these 
repair mechanisms. 
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